Markt oder Branche auswählen:
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| AMAROQ | - | 5 | +1,85 % | ||
 | FESTI | - | 4 | - | |
| HEIMAR | - | 3 | - | |
| JBT MAREL | - | 2 | -0,81 % | ||
| ARION BANK | - | 1 | +0,87 % | ||
| EIMSKIP | - | 1 | - | |
| ICELANDAIR GROUP HF | - | - | - | |
| HAGAR | - | - | - | |
| SKAGI | - | - | - | |
| SJOVA | - | - | - |
- 24 h
- 7 Tage
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Amaroq Ltd.: Holding(s) in Company | 3 | GlobeNewswire (USA) | ||
| Mo | Festi hf.: Publication of Supplement to Base Prospectus | 3 | GlobeNewswire (USA) | ||
| Mo | Alvotech's AVT03 approved by European Commission as biosimilar to Prolia and Xgeva | 6 | Seeking Alpha | ||
| Mo | European Commission approves Alvotech's biosimilar denosumab | 4 | Investing.com | ||
| Mo | Europäische Kommission erteilt Alvotech Zulassung für Denosumab-Biosimilar | 5 | Investing.com Deutsch | ||
| Mo | Alvotech Announces Approval of AVT03, a Biosimilar to Prolia and Xgeva (denosumab) in the European Economic Area | 159 | GlobeNewswire (Europe) | REYKJAVIK, Iceland, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide... ► Artikel lesen | |
| Mo | Eimskipafelag Islands hf.: Transaction in relation to a share buy-back program | 3 | GlobeNewswire (USA) | ||
| Fr | Nasdaq announces semi-annual changes to the OMX Iceland 15 Index: Síldarvinnslan hf. will be added and Skagi hf. will be removed from the Index | 224 | GlobeNewswire | Reykjavik, November 21, 2025 - Nasdaq (Nasdaq: NDAQ) announced today the results of the semi-annual review of the OMX Iceland 15 Index, (Nasdaq Iceland: OMXI15), which will become effective at market... ► Artikel lesen | |
| Fr | Alvotech and Advanz announce EC approval for Gobivaz biosimilar | 5 | Pharmaceutical Business Review | ||
| Fr | Alvotech and Advanz announce EC approval for Gobivaz biosimilar | 4 | Pharmaceutical Technology | ||
| 20.11. | Festi hf.: Major shareholder announcement from Lífeyrissjóður verzlunarmanna | 3 | GlobeNewswire (USA) | ||
| 20.11. | Alvotech - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 20.11. | Alvotech, Advanz Pharma secure European approval for Gobivaz, Simponi biosimilar | 3 | Seeking Alpha | ||
| 20.11. | European Commission approves Alvotech's biosimilar golimumab | 7 | Investing.com | ||
| 20.11. | Alvotech S.A.: Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz, a First-in-Market Biosimilar to Simponi (golimumab) | 977 | GlobeNewswire (Europe) | Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited ("Advanz Pharma"), a... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .